Aelis Farma is a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases.
Aelis Farma is developing a new class of drugs: Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system that provide access to several therapeutic areas without available treatments.
These unique drug candidates, by reproducing a recently discovered natural defense mechanism of the brain , appear to be able to treat various brain pathologies without disrupting normal behavior. A first in pharmacology.
2013
Headcount24
HeadquartersNeurocentre François Magendie 146 Rue Léo Saignat, 33000 Bordeaux – France
12,501,162
IPOFeb. 18, 2022
Stock exchange(s)Euronext Paris